KRAS and neoplasm: Results showed three EGFR mutated tumors (13% of lung AD cases), five K-RAS mutated tumors (two patients; 8.7% of AD cases and three patients; 20% of SCC cases), and one N-RAS mutated tumor (6.7% of SCC cases; Figure 1).